Quanterix’s Post

Sharing one Research Article on #Alzheimer from Nature Portfolio. Welcome to read and share. 'CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease' In this study, they evaluated a new CSF biomarker of insoluble tau aggregates. #Alzheimerdisease #Diagnosticmarkers #Aging #dementia #cognition #brainresearch Click the link and read more: https://rdcu.be/dg4D4

Laverty Pathology is excited to invite you to join our virtual webinar to learn about the new PrecivityAD2™ blood test!   Where: Virtual Date: Tue, Feb 20 Time: 7:30 AM - 8:15 AM GMT+11   This specialty test has been designed for individuals aged 55 and older exhibiting signs of mild cognitive impairment, to aid in the timely diagnosis of Alzheimer's disease.   Our assessment involves analysing plasma for amyloid beta and tau proteins, crucial biomarkers for brain amyloid pathology. Employing cutting-edge LC-MS/MS technology, we precisely measure analyte concentrations and calculate key ratios. Which are then integrated into an analytically and clinically validated algorithm, resulting in the Amyloid Probability Score 2 (out of 100), providing a clear determination of whether the individual is positive or negative for the presence of brain amyloid plaques.   To learn more about this innovative test, sign up for the webinar here: laverty.com.au/c2n-web

QML Pathology is excited to invite you to join our virtual webinar to learn about the new PrecivityAD2™ blood test! Where: Virtual Date: Tue, Feb 20 Time: 7:30 AM - 8:15 AM GMT+10 This specialty test has been designed for individuals aged 55 and older exhibiting signs of mild cognitive impairment, to aid in the timely diagnosis of Alzheimer's disease. Our assessment involves analysing plasma for amyloid beta and tau proteins, crucial biomarkers for brain amyloid pathology. Employing cutting-edge LC-MS/MS technology, we precisely measure analyte concentrations and calculate key ratios. Which are then integrated into an analytically and clinically validated algorithm, resulting in the Amyloid Probability Score 2 (out of 100), providing a clear determination of whether the individual is positive or negative for the presence of brain amyloid plaques. To learn more about this innovative test, sign up for the webinar here: qml.com.au/c2n-web

Alzheimer’s disease research using in vitro human cell models can present challenges in recapitulating the development of toxic amyloid pathology. Click to check out protocol for developing Alzheimer's In A Dish™ , a novel model that presents a valuable tool for studying age-related Alzheimer’s disease dementia, including the production and deposition of amyloid-β and amyloid-β plaques, high levels of phosphorylated tau in the soma and neurites, and the induction of filamentous tau protein.

#DYK: Blood-based biomarkers have the potential to enable non-invasive, cost-effective, and scalable alternatives to aid in assessing amyloid pathology status, a hallmark of Alzheimer’s disease. Learn how blood tests can reduce bottlenecks in physician-led Alzheimer’s diagnosis and treatment. https://bit.ly/3torIy2 #Alzheimers #BloodTest #Neurotherapy

#Diagnostics C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology http://dlvr.it/SxwhS2

Dorevitch Pathology is excited to invite you to join our virtual webinar to learn about the new PrecivityAD2™ blood test!   Where: Virtual Date: Tue, Feb 20 Time: 7:30 AM - 8:15 AM GMT+11   This specialty test has been designed for individuals aged 55 and older exhibiting signs of mild cognitive impairment, to aid in the timely diagnosis of Alzheimer's disease.   Our assessment involves analysing plasma for amyloid beta and tau proteins, crucial biomarkers for brain amyloid pathology. Employing cutting-edge LC-MS/MS technology, we precisely measure analyte concentrations and calculate key ratios. Which are then integrated into an analytically and clinically validated algorithm, resulting in the Amyloid Probability Score 2 (out of 100), providing a clear determination of whether the individual is positive or negative for the presence of brain amyloid plaques.   To learn more about this innovative test, sign up for the webinar here: dorevitch.com.au/c2n-web

In light of the continuous emergence of novel laboratory techniques, I am gaining a profound appreciation for Monash University's mantra, "Ancora Imparo" - meaning "I am still learning." This ethos resonates deeply as a testament to the perpetual pursuit of knowledge and growth in our dynamic field. #continuouslearning #monashuniversity #scientificadvancements

In the Laboratory of Artificial Intelligence Cervical Cancer Screening Center of Yancheng Maternal and Child Health Hospital, is relying on KFBIO high-precision pathology digital slide #scanners, using high-tech #AI analysis software to implement rapid and accurate AI analysis and screening of scanned cervical cell slides, expanding the scope of services, and dedicating itself to enabling every woman to enjoy high-quality cervical cancer screening services. #KFBIO #digitalpathology #artificialintelligence #CervicalCancer

Journal Club: CD69 Deficiency Confers Genetic Susceptibility to Anti-PD1-induced Myocarditis Join expert faculty live TODAY at 14:00 GMT | 09:00 EST🔗 https://ow.ly/tCwI50QvRfz ✨Navigate through the intricate details of this research ✨Receive critical analysis and insightful commentary ✨Get your questions answered #CardioOnc #Cardiology